9. SEGMENTS

12 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

SEGMENTS

9. SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Fiscal Years Ended March 31,
	2020			2019
Revenues:
Aethlon	$	650,187		$	229,625
ESI		–			–
Total Revenues	$	650,187		$	229,625
Operating Losses:
Aethlon	$	(5,899,523	)	$	(5,875,094	)
ESI		(30,465	)		(123,923	)
Total Operating Loss	$	(5,929,988	)	$	(5,999,017	)
Net Losses:
Aethlon	$	(6,349,576	)	$	(6,095,581	)
ESI		(30,465	)		(123,923	)
Net Loss Before Non-Controlling Interests	$	(6,380,041	)	$	(6,219,504	)
Cash:
Aethlon	$	9,604,583		$	3,827,555
ESI		197			519
Total Cash	$	9,604,780		$	3,828,074
Total Assets:
Aethlon	$	10,387,489		$	4,122,445
ESI		197			519
Total Assets	$	10,387,686		$	4,122,964
Capital Expenditures:
Aethlon	$	151,665		$	–
ESI		–			–
Capital Expenditures	$	–		$	–
Depreciation and Amortization:
Aethlon	$	26,366		$	30,695
ESI		–			–
Total Depreciation and Amortization	$	26,366		$	30,695
Interest Expense:
Aethlon	$	54,232		$	220,487
ESI		–			–
Total Interest Expense	$	54,232		$	220,487